ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights
(NASDAQ:PMN), Phase 1b trial in Alzheimer's disease is over 85% enrolled: Cohorts 1 and 2 are fully enrolled PMN310 continues to demonstrate a favorable safety profile On track to report 6-month interim data in Q2 2026 and final 12-month top-line results in Q4 2026 Cambridge, Massachusetts, Nov. 12, 2025 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. […]